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Matrix metalloproteinases are zinc-containing
enzymes capable of degrading all components of
the extracellular matrix. Owing to their role in
human disease, matrix metalloproteinase have
been the subject of extensive study. A bioinor-
ganic approach was recently used to identify
novel inhibitors based on a maltol zinc-binding
group, but accompanying molecular-docking
studies failed to explain why one of these inhibi-
tors, AM-6, had approximately 2500-fold selectiv-
ity for MMP-3 over MMP-2. A number of studies
have suggested that the matrix-metalloproteinase
active site is highly flexible, leading some to
speculate that differences in active-site flexibil-
ity may explain inhibitor selectivity. To extend
the bioinorganic approach in a way that accounts
for MMP-2 and MMP-3 dynamics, we here inves-
tigate the predicted binding modes and ener-
gies of AM-6 docked into multiple structures
extracted from matrix-metalloproteinase molecu-
lar dynamics simulations. Our findings suggest
that accounting for protein dynamics is essential
for the accurate prediction of binding affinity
and selectivity. Additionally, AM-6 and other sim-
ilar inhibitors likely select for and stabilize only a
subpopulation of all matrix-metalloproteinase
conformations sampled by the apo protein. Con-
sequently, when attempting to predict ligand
affinity and selectivity using an ensemble of
protein structures, it may be wise to disregard
protein conformations that cannot accommodate
the ligand.
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Matrix metalloproteinases (MMPs) are zinc-containing enzymes
capable of degrading all components of the extracellular matrix.
They are generally grouped into four classes depending on the
matrix component degraded: collagenases (MMP-1, MMP-8, MMP-
13), gelatinases (MMP-2, MMP-9), stromelysins (MMP-3, MMP-10,
MMP-11), and membrane-type MMPs (MT-MMPs) (1). Owing to
their role in vascular disease (2), asthma (3–5), arthritis, multiple
sclerosis, Alzheimer's disease (6), and cancer (7–9), MMPs have
been the subject of extensive study. To date, several potent inhibi-
tors have been identified, including hydroxamates (10); thiols (11);
carbamoylphosphonates (12,13); hydroxyureas (14,15); hydrazines
(16); b-lactams and squaric acids (17,18); and nitrogenous ligands
(19,20).
Despite the design of these potent inhibitors, thus far only one
MMP inhibitor has been approved by the FDA: periostat (doxy-
cycline hyclate), used for the treatment of periodontitis. Preclinical
studies of other MMP inhibitors have demonstrated severe side
effects caused by inadequate selectivity. Rather than targeting only
the MMP involved in pathogenesis, these compounds generally inhi-
bit multiple MMPs, some of which are actually protective, as well
as other metalloproteinases unrelated to pathology, e.g.,
ADAMs ⁄ adamalysins (21).
Motivated by the urgent need for selective MMP inhibitors, Puerta
et al. recently used a bioinorganic approach to identify novel inhibi-
tors based on a maltol (3-hydroxy-2-methyl-4-pyrone) zinc-binding
group (ZBG). Rather than directly studying compound binding to an
enzymatic active site, these potential ZBGs were screened against
[(TpPh,Me)ZnOH] (TpPh,Me = hydrotris(3,5-phenylmethylpyrazolyl)borate),
a bioinorganic molecular model that mimics the MMP active site
(22) but is more amenable to mechanistic, structural, and spectro-
scopic studies (23–27). Subsequent molecular modeling of the
enzyme active site revealed that combining this ZBG with an amide
linker permits easy access to a hydrophobic, druggable binding
pocket (S1¢) (10,11,28) adjacent to the active-site zinc cation. A
computer fragment-docking program was used to predict the MMP-
2 and MMP-3 binding affinity of several composite compounds
formed by adding small-molecule fragments to the maltol ZBG (29).
X-ray crystallographic data were used to build the receptor models,
and fragments were selected based on the earlier work of Hajduk
et al. (30). Experimental study revealed that three of the composite
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compounds, those formed by adding biphenyl (AM-2), biphenyl cya-
nide (AM-5), and triphenyl (AM-6) fragments to the ZBG, respec-
tively, were selective for MMP-3 over MMP-2 (Table 1). Although
accompanying fragment-docking calculations confirmed AM-2 and
AM-5 selectivity for MMP-3 over MMP-2, these theoretical predic-
tions failed to confirm the approximately 2500-fold selectivity of
fragment AM-6 for MMP-3.
A number of studies have suggested that the MMP active site is
highly flexible, leading some to speculate that differences in active-
site flexibility among the different MMPs could explain specificity. In
their previous work, Yuan et al. (31) studied the backbone amide
dynamics of the MMP-3 catalytic domain using 15N NMR relaxation
measurements. Hydroxamate- and thiadiazole-containing ligands,
which bind to the S1¢–S3¢ (right side) and S1–S3 (left side) regions of
the active site (Figure S1), respectively, were used to identify inhibi-
tor-specific changes in the molecular dynamics (MD) of the catalytic
domain. Yuan et al. also observed that the S1–S3 binding pockets
were relatively rigid, while the S1¢–S3¢ pockets were highly flexible.
In another study, de Oliveira et al. carried out MD simulations to
evaluate the dynamics of MMP-2 and MMP-3 free in solution. The
authors confirmed that the S1¢–S3¢ pockets are highly mobile in both
systems while further demonstrating that the MMP-2 and MMP-3
S1¢ binding pockets nevertheless have markedly different dynamics.
Specifically, MMP-3 tends to sample states in which the hydropho-
bic, tunnel-like S1¢ pocket is often fully open, while MMP-2 tends to
sample states in which the S1¢ pocket is closed or at the most only
partially open. By directly measuring the S1¢ pocket volumes of
MMP structures extracted from MD simulations, Durrant et al. (32)
further confirmed that MMP-3 tends to be either fully open or
closed, while MMP-2 is more apt to adopt intermediate states.
These studies suggest that accounting for protein flexibility may be
critical for the accurate prediction of small-molecule binding affini-
ties in silico. To extend the bioinorganic approach in a way that
properly accounts for MMP-2 and MMP-3 dynamics, we here inves-
tigate the predicted binding modes and affinities of the ZBG-AM-
2, ZBG-AM-5, and ZBG-AM-6 compounds docked into multiple
structures extracted from MMP-2 and MMP-3 MD simulations. Our
findings suggest that these inhibitors select only those MMP con-
formations that are amenable to S1¢ binding. In trying to predict
selectivity, protein conformations that cannot accommodate the
ligand should be disregarded.
For MMP-2, the S1¢ pocket adopts a continuous spectrum of confor-
mations from closed to open. The occasional fully open conforma-
tions, as well as many of the intermediate conformations, have S1¢
pockets that can accommodate a bound ligand. MMP-3 dynamics,
on the other hand, are more binary, with S1¢ pockets that are gen-
erally either fully open or closed. It is only when the closed MMP-3
conformations are disregarded that the selectivity of all three inhibi-
tors can be correctly predicted, suggesting that the compounds may
in fact select for and stabilize accommodating protein conformations
in vitro.
Methods and Materials
Molecular Dynamics (MD) simulations
The crystal structures of human matrix metalloproteinase-2 (MMP-2,
PDB ID: 1QIB) and matrix metalloproteinase-3 (MMP-3, PDB ID:
1G4K) were used to build the initial models. Basic residues like argi-
nine and lysine were protonated, and acidic residues like aspartate
and glutamate were deprotonated. The histidine residues were
assumed to be neutral at physiological pH. Except for the histidine
residue located in the structural domain (His 179), which was proton-
ated in the epsilon position, all histidine residues were protonated in
the delta position. To maintain the correct orientation of the struc-
tural and catalytic zinc and histidine residues, the distances and
bending angles defined by the zinc and the coordinating histidine
nitrogen atoms were maintained by applying harmonic restraints. The
partial charges of the imidazole rings of the histidine residues and
the zinc atom were calculated using the RESP program (Figure S2,
Table S1). The molecular electrostatic potential was calculated at
the HF ⁄ 6-31G* level. All other protein residues were assigned partial
charges according to the AMBER-99SB force field (33).
Following the initial preparation, each system was subjected to 500
steps of steepest-descent and 1000 steps of conjugate-gradient min-
imization. Each of the minimized structures was then solvated in
cubic boxes of pre-equilibrated TIP3P water molecules (34) extending
10  beyond the protein atoms themselves in all three dimensions.
Sodium cations were next added to each system as needed to
ensure electrical neutrality. The systems were again minimized for
500 steps of steepest-descent followed by 2000 steps of conjugate-
gradient minimization using constant-volume periodic boundaries,
with the protein and counterion atoms fixed, to relax the waters.
To achieve the correct system density, each system was next sub-
jected to 50 ps of MD simulation with an NPT ensemble
(T = 298 K, P = 1 bar) in which only the water molecules were
allowed to move. Next, the systems were again energy minimized
Table 1: Experimentally measured IC50 values (lM) for the inhib-
itors AM-2, AM-5, and AM-6 against MMP-2 and MMP-3a
ID Inhibitor MMP-2 MMP-3
AM-2 9.3 0.24
AM-5 0.61 0.010
AM-6 >50 0.019
aTaken from reference (29); MMP, matrix metalloproteinases.
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for 500 steps of steepest descent and 1000 steps of conjugate-gra-
dient minimization. To heat each system, a 500-ps MD simulation
using the NVT ensemble (T = 298 K) was performed, where the
temperature varied gradually from 0 to 300 K. The systems were
further relaxed by applying 40 ns of MD simulation using the NVT
ensemble at constant temperature (T = 298 K). During the NVT sim-
ulations, all atoms were allowed to move freely, except for those
subject to the aforementioned internal restraints, as well as those
subject to SHAKE constraints placed on bonds to hydrogen atoms
(35). All minimizations and MD simulations were carried out using
the AMBER MD computer package (36).
Positioning the ZBG and fragment docking
Five thousand frames were extracted at regularly spaced intervals
from both the MMP-2 and the MMP-3 simulations. These 5000
frames were aligned by the atoms of their active-site zinc cations
and the three coordinating histidine residues (Figure 1A). A crystal
structure of maltol bound to [(TpPh,Me)ZnOH], a bioinorganic model
of the MMP active site, was then used to position the maltol ZBG
correctly relative to the aligned frames (Figure 1B).
For each of the 5000 frames of both simulations, the docking pro-
gram LUDI [Accelrys (37–39)] was used to dock three small-mole-
cule fragments (AM-2, AM-5, and AM-6) into the active-site-
positioned maltol ZBG (Figures 1C and 2), producing a spectrum of
LUDI scores from which ensemble averages were ultimately calcu-
lated (Figure 1D). The ZBG amine hydrogen atom that pointed
toward the S1¢ pocket was selected as the link site. The following
LUDI parameters were used: maximum alignment angle 20, maxi-
mum alignment root-mean-square deviation (RMSD) 0.6 , search
radius 11 , rotate bonds two at a time, preselect 4.0, minimum
separation 3.0, lipophilic density 40, polar density 40, minimum sur-
face 0, link weight 1.0, lipophilic weight 1.0, H-bond weight 1.0, ali-
phatic aromatic off, reject bifurcated off, no unpaired polar off,
electrostatic check off, minimum score 0, maximum fits 8000, maxi-
mum hits all, maximum unfilled cavity 0, energy estimate 1 scoring
function, and best fit.
Determining the binding mode
Analysis of the LUDI docking results revealed two possible binding
modes: one in which the added fragment fit deeply into the S1¢
pocket (Figure 3C) and another in which S1¢ was not amenable to
deep binding (Figure 3B). To distinguish between these two bind-
ing modes, for each frame we calculated the distance between a
key S1¢ carbonyl oxygen atom and the nearest atom of the LUDI-
docked fragment. The carbonyl oxygen atoms of leucine 115
and leucine 111 were used for MMP-3 and MMP-2, respectively.
If this distance was <5 , the fragment was thought to bind
deep in the S1¢ pocket. Otherwise, binding was considered to be
superficial.
A B D
C
Figure 1: The molecular dynamics (MD) ⁄ docking protocol. The matrix metalloproteinase (MMP) protein is shown in blue, the active-site
zinc cation is shown in brown, the zinc-coordinating histidine residues are shown in green, and representative LUDI-docked fragments are
shown in pink. (A) A MD simulation was used to generate numerous MMP conformations. (B) A model of the zinc-binding group was posi-
tioned relative to the protein configurations by aligning a crystal structure of the bioinorganic model to the MMP active sites. (C) LUDI was
used to dock molecular fragments into the S1¢ active sites. (D) The resulting spectrums of LUDI scores were subsequently used to calculate
ensemble-average scores.
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Results and Discussion
The purpose of this study is to extend the bioinorganic approach
originally pioneered by Puerta et al. (29) in a way that properly
accounts for MMP-2 and MMP-3 dynamics. To understand the
molecular basis of the observed MMP-3 selectivity of ZBG + amide
linker + AM-6 (Figure 2), we explored the role protein flexibility
might play in inhibitor binding for this system.
Figure 2: LUDI-score histograms. Fragments attached to the zinc-binding group via an amide linker (R = AM-2, AM-5, or AM-6) were
docked into frames extracted from apo molecular dynamics simulations of MMP-2 and MMP-3. The LUDI scores were binned into histograms
according to the docked fragment and receptor target. Note that a different scale has been used for AM-6 to facilitate visualization.
A B C
Figure 3: Three distinct conformations of the matrix-metalloproteinase active site, extracted from an molecular dynamics simulation. Some
protein residues have been removed to facilitate visualization. The protein is shown in gray, the active-site zinc cation is shown in ice blue,
and the ligand is colored by element. (A) Some protein conformations were not amenable to fragment addition. (B) Other conformations were
amenable to fragment addition but did not allow deep binding to the S1¢ subsite. (C) Others were amenable to both fragment addition and
deep binding.
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The importance of protein flexibility
Numerous studies have demonstrated the important role of protein
flexibility in ligand binding (40–45). For example, a recent MD simu-
lation of HIV integrase revealed a previously uncharacterized bind-
ing trench that was not apparent from inspection of the static
crystal structures alone. This trench was subsequently exploited in
the design of Isentress (raltegravir), an HIV drug approved by the
FDA in 2007 (42). A recent MD simulation of cruzain, the principal
cysteine protease of the eukaryotic parasite Trypanosoma cruzi, like-
wise revealed a potentially druggable 'cryptic binding site' (46).
Accounting for protein flexibility can also improve the accuracy of
virtual screening. For example, in a new virtual-screening protocol
called the relaxed complex scheme (40), a library of compounds is
docked into multiple protein conformations extracted from an MD
simulation to account for full protein flexibility. When the com-
pounds are ranked by an ensemble-based score rather than by the
score associated with docking to the static crystal structure alone,
hit rates are often improved. The relaxed complex scheme has
been used to identify inhibitors of FKBP (47), HIV integrase (42),
Trypanosoma brucei RNA editing ligase 1 (44), and T. brucei UDP-
galactose 4¢-epimerase (48), among others.
As NMR, X-ray crystallographic, and MD-simulation studies have
shown that MMPs have highly flexible active sites (32,49–54),
accounting for protein flexibility may be especially important when
trying to predict MMP-ligand binding. More specifically, MD studies
have revealed a highly dynamic S1¢ pocket that can adopt both
open- and semi-open conformations capable of accommodating
large hydrophobic fragments, as well as closed conformations not
amenable to binding (Figure 3). These simulations further suggest
that MMP-2 heavily samples semi-open (intermediate) and closed
states, while MMP-3 tends to sample either the fully closed or the
fully open state. By docking fragments only into the static crystal
structures of these proteins, the LUDI protocol used by Puerta et al.
(29) did not account for the many receptor configurations sampled
by these dynamic macromolecules. This oversight could potentially
explain why previous computer calculations have failed to predict
the >2500-fold MMP-3 selectivity of the AM-6 inhibitor.
Novel fragment docking into conformations
extracted from an MD simulation
Recognizing that LUDI docking into static crystal structures fails to
fully explain MMP-3 selectivity, we tested the hypothesis that
accounting for full protein flexibility might improve prediction by
docking AM-2, AM-3, and AM-6 into 5000 protein configura-
tions extracted from MD simulations of MMP-2 and MMP-3,
respectively. Given that a significant number of the apo structures
sampled by the MD simulations are not able to accommodate the
molecular fragments, we hypothesized that conformational selection
may play an important role in MMP inhibitor binding.
Figure 2 illustrates the LUDI fragment score distributions generated
by docking into the MMP-2 and MMP-3 MD trajectories. The histo-
grams of the docking scores obtained for AM-2, AM-5, and AM-
6 hint at the differences in the dynamics of the MMP-2 and MMP-
3 S1¢ pockets identified previously. Clearly, these differing dynamics
have a significant impact on the docking results; while the score
distributions associated with MMP-2 were unimodal for all frag-
ments, those associated with MMP-3 were bimodal for AM-2 and
AM-5, and unimodal for AM-6. Bimodal distributions suggest
multiple binding modes; visual inspection of the binding poses con-
firmed that the higher LUDI scores were consistently associated
with fragments that docked deep within the S1¢ pocket. In contrast,
the lower LUDI scores were associated with fragments that docked
into a shallow, closed, or semi-closed S1¢ pocket conformation (Fig-
ure 3B,C).
The bimodal LUDI score distributions of MMP-3 demonstrate a
clear separation between the constituent distributions characterizing
each binding mode. In the case of AM-6 docked into MMP-3, the
distribution is likely unimodal only because the bulky AM-6 frag-
ment could not dock into a shallow, closed, or semi-closed S1¢ pocket
at all. These findings are in good agreement with our previous MD
simulations, which show that the open and closed form of the S1¢
binding pocket are indeed the most populated conformational states
sampled by MMP-3, with few intermediate states (32,54).
The LUDI score distributions associated with MMP-2 likewise show
good agreement with previous MD results. For MMP-2, the S1¢
pocket breathes continuously from a closed to an open conforma-
tion and so can generally accommodate a bound molecular frag-
ment. The MMP-2 MD trajectory sampled a wide range of
intermediate conformational states between fully open and closed.
Consequently, a unimodal score distribution is observed for AM-2
and AM-5 docked into the MMP-2 active site. Even if the distribu-
tion associated with AM-6 is considered to be bimodal, the mode
associated with the higher LUDI score is only rarely sampled.
Regardless, this higher-score state is considerably less populated in
MMP-2 than in MMP-3, where it is the only mode sampled.
Interpretation of results, agreement with
experiment
Emil Fischer (55) first proposed the lock-and-key model of ligand
binding in 1894. While didactically useful, this model, which sug-
gests that a protein exists in a single conformation that is perfectly
complimentary to the ligand it binds, has fallen out of favor in light
of crystallographic and NMR evidence (56–58). A number of sub-
sequent theories have been presented describing the important role
protein flexibility plays in ligand binding (59). In recent years,
researchers have begun to theorize that binding often occurs via a
population-shift mechanism, commonly called conformational selec-
tion (60–63). The theory states that an apo protein, in constant
motion as it 'breaths' in solution, continuously samples many differ-
ent active-site conformations. Only a certain subpopulation of these
conformations is amenable to ligand binding. In the presence of a
ligand, this amenable subpopulation is stabilized (i.e., 'selected'),
causing the population of conformations to shift away from those
that are incompatible with binding.
Drawing on the theory of conformational selection, we postulate
that in the case of the MMPs only ligand binding deep within the
S1¢ pocket is truly representative of bound complexes in vitro. As
MMP-3 rarely samples intermediates states (i.e., the semi-open
Pyrone-Based MMP Inhibitors
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states of the S1¢ pocket), the fragments AM-2, AM-5, and AM-
6 can only bind to, or select, conformational states in which the
S1¢ pocket is fully open. We consequently discarded those MMP-3
conformations with closed S1¢ pockets when calculating the ensem-
ble-average LUDI scores. In contrast, to properly calculate the
ensemble-average LUDI scores of MMP-2 binding, we considered
all conformational states because intermediate semi-open S1¢ pock-
ets amenable to ligand binding are commonly sampled.
The calculated average LUDI scores of AM-6 bound to MMP-2
and MMP-3 were 440.1 € 95.6 and 697.1 € 52.1, respectively.
Because each 100 LUDI score units corresponds to an IC50 increase
of one order of magnitude (37,64), our results are in excellent
agreement with the three-order-of-magnitude difference obtained
experimentally (IC50 values of >50 and 0.019 lM for MMP-2 and
MMP-3, respectively; Table 1) (29). The same agreement with exper-
iment is observed when a similar protocol is applied to AM-2 and
AM-5. The average LUDI score of AM-2 bound to MMP-2 and
MMP-3 was 413.1 € 76.3 and 534.6 € 94.2, respectively. The
roughly 100 units difference is in good agreement with the experi-
mentally measured IC50 values of 9.3 and 0.24 lM, respectively
(Table 1). Similarly, the average LUDI score of AM-5 bound to
MMP-2 and MMP-3 was 431.3 € 69.9 and 567.4 € 84.9, respec-
tively, again comparing well with the experimentally measured IC50
values (0.61 and 0.01 lM, respectively; Table 1). We note that this
agreement with experiment was not obtained when the closed
MMP-3 conformations were retained in the calculation, suggesting
that they are not biologically relevant to binding in vitro.
Conclusions
Based on this analysis, our results suggest that the ZBG with
attached fragments AM-2, AM-5, and AM-6 may bind to
MMP-2 and MMP-3 via a conformational selection mechanism.
The dynamics of the S1¢ binding pocket reveal that the receptor
samples three principal conformational states: (a) fully closed,
incompatible with binding ⁄ docking (no LUDI scores, Figure 3A); (b)
semi-open, compatible with weak binding (Figure 3B); and (c) fully
open, compatible with strong binding (corresponding to the higher
mode of the LUDI score distributions, Figure 3C).
These results confirm the findings of previous studies that suggest
that accounting for protein flexibility is critical to the theoretical
prediction of small-molecule binding affinities, especially when
studying MMPs. Our ensemble-based docking analyses also indicate
that differences in the dynamics of MMP-2 and MMP-3 likely
explain the selectivity of the AM-6 compound for MMP-3.
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